Literature DB >> 1195128

Effect of portacaval shunt on the disposition of drugs with and without first-pass effect.

R Gugler, P Lain, D L Azarnoff.   

Abstract

The pharmacokinetic parameters of lidocaine, antipyrine and salicylamide were studied in dogs before and after construction of a portacaval shunt. The systemic availability of antipyrine was not altered significantly by the surgical procedure whereas the availability of lidocaine and salicylamide, drugs with a marked first-pass effect, was increased from 14.8 +/- 2.8 to 81.3 +/- 5.2% and from 21.8 +/- 7.8 to 57.5 +/- 2.5%, respectively. Of the 78% first-pass extraction of salicylamide, 36% is due to hepatic extraction whereas the remaining 42% is accounted for by intestinal wall extraction. The presence of a portacaval shunt also reduced the plasma clearance of lidocaine and antipyrine, but not salicylamide. The apparent volume of distribution was decreased only with salicylamide. Surgical construction of a portacaval shunt in dogs in a good model to evaluate first-pass effect. Physicians should adjust downward the dose of drugs with a first-pass effect. Physicians should adjust downward the dose of drugs with a first-pass effect in patients with a surgical portacaval shunt or endogenous portal systemic shunts such as seen in cirrhosis of the liver.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1195128

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Pharmacokinetics of oral terbinafine in horses and Greyhound dogs.

Authors:  M M Williams; E G Davis; B KuKanich
Journal:  J Vet Pharmacol Ther       Date:  2011-06       Impact factor: 1.786

2.  Time-dependent modifications of splanchnic circulation in female pigs submitted to end-to-side portacaval anastomosis.

Authors:  G Molino; P Avagnina; C Garrone; G Sansoè; M M Degerfeld; P Peretti; M Tinivella; S Bianco
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

3.  Sites of first-pass bioactivation (hydrolysis) of orally administered zofenopril calcium in dogs.

Authors:  R A Morrison; D E Burkett; M E Arnold; C J D'Arienzo; S H Weinstein
Journal:  Pharm Res       Date:  1991-03       Impact factor: 4.200

Review 4.  Hepatic first-pass metabolism in liver disease.

Authors:  T F Blaschke; P C Rubin
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

5.  The influence of cirrhosis on steady-state blood concentrations of unbound propranolol after oral administration.

Authors:  A J Wood; D M Kornhauser; G R Wilkinson; D G Shand; R A Branch
Journal:  Clin Pharmacokinet       Date:  1978 Nov-Dec       Impact factor: 6.447

6.  Influence of meso-caval shunt surgery on verapamil kinetics, bioavailability and response.

Authors:  M Eichelbaum; M Albrecht; G Kliems; K Schäfer; A Somogyi
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

Review 7.  Protein binding and kinetics of drugs in liver diseases.

Authors:  T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of lignocaine.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

Review 9.  Propranolol disposition in chronic liver disease: a physiological approach.

Authors:  R A Branch; D G Shand
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

10.  Plasma concentrations and central nervous system effects of the new hypnotic agent zopiclone in patients with chronic liver disease.

Authors:  G Parker; C J Roberts
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.